Moderna Stock ( NASDAQ:MRNA )
The management of Moderna ( NASDAQ:MRNA ) announced that the pivotal phase III ConquerRSV study evaluating mRNA-1345 , the company’s mRNA-based respiratory syncytial virus (RSV) vaccine, had achieved the primary efficacy endpoints, which caused Moderna stock price to surge 6.5% in after-market trading on January 17.
Moderna is a Cambridge, Massachusetts-based pharmaceutical and biotechnology company that focuses on RNA therapeutics, primarily mRNA vaccines. To elicit an immune response, these vaccines employ a copy of a molecule known as messenger RNA.
An Efficient and Well-Tolerated Vaccine
RSV-associated lower respiratory tract disease (RSV-LRTD) is defined as two or more symptoms of the disease in older adults. The ConquerRSV study , which evaluated mRNA-1345 in older adults aged 60 years and above, achieved vaccine efficacy of 83.7% against RSV-associated lower respiratory tract disease (RSV-LRTD). Additionally, the vaccination demonstrated efficacy of 82.4% against RSV-LRTD, which is characterized by the presence of three or more symptoms. It was found that mRNA-1345 was well tolerated, and there were no safety issues found.
On the basis of these data, management anticipates submitting mRNA-1345 for regulatory approval during the first half of the year 2023.
These findings are based on a preliminary investigation of 64 patients diagnosed with RSV-LRTD who had two or more symptoms. While the study is currently in pr...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube